BRAF and central nervous system cancer: Even though the most recent studies used the combination of BRAFis and MEKis, and some studies suggest that the combination provides better disease control and decreases adverse events [17,18], our group felt it was reasonable to use BRAFis as monotherapy for some patients with BRAF V600E mutant gliomas.